Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

May 31, 2011

Conditions
Carcinoma, Non Small Cell Lung
Interventions
DRUG

ZD6474 (vandetanib)

vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days

DRUG

Faslodex (Fulvestrant)

Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

University of Pittsburgh

OTHER

lead

University of Wisconsin, Madison

OTHER